Table 5. Univariate and multivariate biomarker performance in 0-1 year time group and for all pre-diagnosis samples.
| Time group (years) | Biomarker(s) | Sensitivity (95% CI) | Specificity (95% CI) | AUC (95% CI) |
|---|---|---|---|---|
| 0–1 (n = 10) | CA19-9 | 80.0 (44.4–97.5) | 69.2 (58.7–78.5) | 0.770 (0.577–0.963) |
| TBIL | 70.0 (34.8–93.3) | 69.2 (58.7–78.5) | 0.651 (0.458–0.845) | |
| PKM2 | 60.0 (26.2–87.8) | 50.0 (39.9–61.2) | 0.525 (0.358–0.693) | |
| CRP | 70.0 (34.8–93.3) | 73.6 (63.3–82.3) | 0.728 (0.525–0.930) | |
| GGT | 90.0 (55.5–99.8) | 65.9 (55.3–75.6) | 0.793 (0.628–0.958) | |
| ALP | 80.0 (44.4–97.5) | 63.7 (53.0–73.6) | 0.771 (0.636–0.906) | |
| CA19-9; PKM2 | 50.0 (20.0–80.0) | 90.1 (74.7–100) | 0.781 (0.580–0.983) | |
| CA19-9; CRP | 60.0 (30.0–90.0) | 90.1 (58.2–100) | 0.812 (0.615–1.00) | |
| CA19-9; ALP | 60.0 (30.0–90.0) | 90.1 (40.7–100) | 0.824 (0.661–0.988) | |
| CA19-9; PKM2; LRG; IL6 | 60.0 (20.0–80.0) | 90.1 (35.2–100) | 0.803 (0.627–0.979) | |
| All (n = 89) | CA19-9 | 52.8 (41.9–63.5) | 69.2 (58.7–78.5) | 0.633 (0.552–0.715) |
| TBIL | 42.7 (32.3–53.6) | 67.0 (56.4–76.5) | 0.505 (0.419–0.590) | |
| PKM2 | 59.6 (48.6–69.8) | 50.6 (39.9–61.2) | 0.529 (0.444–0.614) | |
| CRP | 60.7 (49.8–70.9) | 64.8 (54.1–74.6) | 0.646 (0.565–0.727) | |
| GGT | 49.4 (38.7–60.3) | 71.4 (61.0–80.4) | 0.589 (0.505–0.673) | |
| CA19-9; CRP | 33.7 (14.6–48.3) | 90.1 (78.0–95.6) | 0.689 (0.611–0.767) | |
| CA19-9; PKM2; LRG1; IL6 | 29.2 (11.2–40.5) | 90.1 (75.8–95.6) | 0.640 (0.559–0.722) |